AKE-72

CAS No. 2566525-18-4

AKE-72( —— )

Catalog No. M37282 CAS No. 2566525-18-4

AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 240 Get Quote
5MG 372 Get Quote
10MG 546 Get Quote
25MG 815 Get Quote
50MG 1095 Get Quote
100MG 1467 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AKE-72
  • Note
    Research use only, not for human use.
  • Brief Description
    AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.
  • Description
    AKE-72 (compound 5) is a potent inhibitor of Pan-BCR-ABL. AKE-72 inhibits BCR-ABLWT, BCR-ABLT315, BCR-ABLE255K, BCR-ABLF3171, BCR-ABLH396P and BCR-ABLQ252H with IC50s of < 0.5, 9, 8.98, 3.12, < 1.0 and 3.88 nM, respectively. AKE-72 has anti-leukemic activity against K-562 cell line.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Bcr-Abl
  • Recptor
    Bcr-Abl
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2566525-18-4
  • Formula Weight
    546.59
  • Molecular Formula
    C30H29F3N6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=CC=C(C(=C1)C(F)(F)F)CN2CCN(CC)CC2)C=3C=CC=C(C#CC4=CC=CC=5NN=C(N)C45)C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. 3-((3-amino-1H-indazol-4-yl)ethynyl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (AKE-72), a potent Pan-BCR-ABL inhibitor including the T315I gatekeeper resistant mutant. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2228515.?
molnova catalog
related products
  • DPH

    A cell-permeable, small-molecule c-Abl kinase activator with pEC50 of 6.1(EC50=794 nM).

  • Vodobatinib

    Vodobatinib is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.

  • XL228

    XL228 is an inhibitor of multi-targeted tyrosine kinase.